Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
PolyPid has regained exclusive European commercialization rights for its D-PLEX100 drug by terminating its 2022 agreement with ADVANZ PHARMA. This strategic shift follows recent Phase 3 success and submissions for regulatory approval in Europe and the US, prompting PolyPid to seek new partnerships.
PolyPid Ltd. announced it has regained the European commercialization rights for its D-PLEX100 product from ADVANZ PHARM. This move expands the company's global commercialization opportunities.
PolyPid said it regained European commercialization rights for D-PLEX100, expanding its commercialization opportunities.